Get started
Author

Nirjhar Chakraborty

Observed name: Chakraborty, Nirjhar
ORCID: 0009-0003-8104-4311
Observed ORCID: 0009-0003-8104-4311
OpenAlex ID: A5026412359
Quality of Treatment Selection for Medicare Beneficiaries With Cancer
2024 · Aaron P. Mitchell, Sonia Persaud, et al. · Journal of Clinical Oncology · 10
Persistence of Telemedicine Usage for Breast and Prostate Cancer after the Peak of the COVID-19 Pandemic
2023 · Susan Chimonas, Allison Lipitz-Snyderman, et al. · Cancers · 8
PDF
Implementation Strategies to Promote Short-Course Radiation for Bone Metastases
2024 · Erin F. Gillespie, Patricia Mae G. Santos, et al. · JAMA Network Open · 6
Provider billing margin and cancer treatment selection: population based cohort study
2025 · Aaron P Mitchell, Stacie B Dusetzina, et al. · BMJ · 3
PDF
Trends in enforcement of National Comprehensive Cancer Network financial conflict of interest policy
2024 · Niloufar Saririan, Dedipya Bhamidipati, et al. · JNCI Cancer Spectrum · 3
Trends in financial payments from industry to US cancer centers, 2014-2021
2024 · Nirjhar Chakraborty, Meredith Brown, et al. · JNCI Cancer Spectrum · 3
Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer
2024 · Aaron P. Mitchell, David Nemirovsky, et al. · JCO Oncology Practice · 2
PDF
CCDC 2517104: Experimental Crystal Structure Determination
2026 · Barman, Nandini, Mondal, Prakash, et al. · The Cambridge Structural Database · 1
Changes in Cost of Guideline-Concordant Cancer Treatment: Observations and Implications
2025 · Judy J. Wang, Sonia Persaud, et al. · JCO Oncology Practice · 1
Cost trends in standard-of-care cancer treatments, 2017-2021.
2024 · Judy J. Wang, Sonia Persaud, et al. · Journal of Clinical Oncology · 1
Cost to Medicare from bone modifying agent overuse in castration-sensitive prostate cancer.
2023 · Aaron Philip Mitchell, Nirjhar Chakraborty, et al. · JCO Oncology Practice · 1
PDF
Quality of treatment selection for Medicare beneficiaries with cancer.
2023 · Sonia Persaud, Aaron Philip Mitchell, et al. · JCO Oncology Practice · 1
PDF
Improving the use of bone modifying agents for patients with prostate cancer.
2026 · Aaron Philip Mitchell, Andrew L. Salner, et al. · JCO Oncology Practice
Oncologists’ acceptance of personal financial payments from drug manufacturers and use of aggressive end-of-life care.
2026 · Aaron Philip Mitchell, Stacie B. Dusetzina, et al. · JCO Oncology Practice
PDF
340b hospital participation and initial oncology treatment choice.
2026 · Nina Galanter, Ziad Zakaria, et al. · JCO Oncology Practice
PDF
Conceptualizing time toxicity in cancer care: A qualitative study to inform measure development.
2026 · Erin Mary Bange, Amy McArthur, et al. · JCO Oncology Practice
PDF
Hospital clinical trial enrollment volume and long-term survival among older adults with cancer.
2026 · Allison Lipitz-Snyderman, Gabrielle Guzman, et al. · JCO Oncology Practice
PDF
Financial Payments From Drug Manufacturers to Oncologists and Use of Guideline-Preferred Cancer Treatments
2026 · Aaron P. Mitchell, Aaron N. Winn, et al. · Journal of Clinical Oncology
Quality, Cost, and Timeliness of Cancer Treatment in Medicare Advantage and Traditional Medicare
2026 · Aaron P. Mitchell, Stacie B. Dusetzina, et al. · JAMA Internal Medicine
Association of drug industry payments to oncologists and use of guideline-preferred cancer treatments.
2026 · Aaron Philip Mitchell, Aaron N. Winn, et al. · Journal of Clinical Oncology
PDF
Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer
2025 · Aaron P. Mitchell, Andrew Salner, et al. · JCO Oncology Practice
Variation in guideline-concordant use of bone modifying agents for prostate cancer.
2025 · Aaron Philip Mitchell, Andrew L. Salner, et al. · JCO Oncology Practice
PDF
The association between profitability, clinical benefit, and physicians’ selection of cancer drugs.
2025 · Aaron Philip Mitchell, Stacie B. Dusetzina, et al. · Journal of Clinical Oncology
Oncologists’ management of non-cancer conditions: An observational study.
2024 · Kanan Shah, Grace B. Gallagher, et al. · JCO Oncology Practice
Trends in pharmaceutical industry payments to US cancer centers, 2014-2021.
2024 · Aaron Philip Mitchell, Nirjhar Chakraborty, et al. · Journal of Clinical Oncology
PDF
Works count: 26
Citation count: 40
H-index: 3
I10-index: 1
Year
Topic
Type